Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism

National Yang Ming Chiao Tung University

Status: Enrolling

Conditions: Osteoporosis

Treatments: Dietary Supplement: Stage 2; Dietary Supplement: Stage 1

Study type: Interventional

Funder types: Other

Identifiers

NCT06372158

NYCU112181AE

Details and patient eligibility

About

Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium. This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time. Liposomal calcium can be taken orally directly. It does not need to be dissolved in water before taking like other calcium supplements, making it more convenient to use. Based on the above advantages, liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for long-term use, and can meet the body's demand for calcium. According to the recommendations of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg. In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for Chinese people recommends that the daily intake for adults should be 1,000 mg. The calcium dose used in this study was 500 mg. The purpose was to explore whether the sustained-release characteristics of liposome coating technology can improve the absorption rate after consuming calcium powder and achieve better bioavailability. It is expected that microlipids made by lecithin can Lipid calcium powder increases its maintenance time in the blood, thereby increasing the supplementary effect of calcium, and is an alternative to calcium supplements.

Enrollment: 20 estimated patients

Sex: All

Ages: 20 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults aged 20-60 years old, without heart, liver, kidney, endocrine or major organic diseases (patient report), and able to fully cooperate with the experiment.

Exclusion criteria

1. Patients with renal insufficiency and dialysis
2. Cancer patients
3. Underweight (BMI#17) or obese (BMI#27)
4. Those taking medications for chronic diseases
5. Blood pressure systolic blood pressure # 130 mmHg or diastolic blood pressure # 85 mmHg
6. Fasting blood glucose # 100 mg/dL
7. Fasting triglycerides # 150 mg/dL, total cholesterol # 200 mg/dL
8. Have a history of vitamin C allergy
9. People suffering from mental illness
10. Pregnant and breastfeeding women
11. Patients with hemosiderosis
12. Kidney stone patients
13. Supplements for those who take calcium for a long time

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

20 participants in 2 patient groups

Stage 1

Other group

Description:

Day 14

Treatment:

Dietary Supplement: Stage 1

Stage 2

Other group

Description:

Day 28

Treatment:

Dietary Supplement: Stage 2